A Synopsis of Hepatitis C Virus Treatments and Future Perspectives
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73621467" target="_blank" >RIV/61989592:15110/23:73621467 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15640/23:73621467
Result on the web
<a href="https://www.mdpi.com/1467-3045/45/10/521" target="_blank" >https://www.mdpi.com/1467-3045/45/10/521</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cimb45100521" target="_blank" >10.3390/cimb45100521</a>
Alternative languages
Result language
angličtina
Original language name
A Synopsis of Hepatitis C Virus Treatments and Future Perspectives
Original language description
Hepatitis C virus (HCV) infection is a worldwide public health problem. Chronic infection with HCV can lead to liver cirrhosis or cancer. Although some immune-competent individuals can clear the virus, others develop chronic HCV disease due to viral mutations or an impaired immune response. IFNs type I and III and the signal transduction induced by them are essential for a proper antiviral effect. Research on the viral cycle and immune escape mechanisms has formed the basis of therapeutic strategies to achieve a sustained virological response (SVR). The first therapies were based on IFN alpha; then, IFN alpha plus ribavirin (IFN-RBV); and then, pegylated-IFN alpha-RBV (PEGIFN alpha-RIV) to improve cytokine pharmacokinetics. However, the maximum SVR was 60%, and several significant side effects were observed, decreasing patients' treatment adherence. The development of direct-acting antivirals (DAAs) significantly enhanced the SVR (>90%), and the compounds were able to inhibit HCV replication without significant side effects, even in paediatric populations. The management of coinfected HBV-HCV and HCV-HIV patients has also improved based on DAA and PEG-IFN alpha-RBV (HBV-HCV). CD4 cells are crucial for an effective antiviral response. The IFN lambda 3, IL28B, TNF-alpha, IL-10, TLR-3, and TLR-9 gene polymorphisms are involved in viral clearance, therapeutic responses, and hepatic pathologies. Future research should focus on searching for strategies to circumvent resistance-associated substitution (RAS) to DAAs, develop new therapeutic schemes for different medical conditions, including organ transplant, and develop vaccines for long-lasting cellular and humoral responses with cross-protection against different HCV genotypes. The goal is to minimise the probability of HCV infection, HCV chronicity and hepatic carcinoma.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/LX22NPO5103" target="_blank" >LX22NPO5103: National Institute of Virology and Bacteriology</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Issues in Molecular Biology
ISSN
1467-3037
e-ISSN
1467-3045
Volume of the periodical
45
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
22
Pages from-to
"8255 "- 8276
UT code for WoS article
001096530900001
EID of the result in the Scopus database
2-s2.0-85175040315